A Study of Buntanetap in Participants With Parkinson's Disease
This study is looking at the long-term safety of a drug called buntanetap in people with Parkinson's Disease (PD). It will last for 36 months (3 years). There are two groups of participants: one group includes people who have already taken part in buntanetap studies, and the other group includes people with PD who are receiving deep brain stimulation (DBS) treatment. The main goal is to see how safe buntanetap is by tracking any side effects over this long period. The study aims to enroll 500 participants aged 40 to 85 years old. The current recruitment status is unclear.
- Study design
- This is an open-label safety study, meaning both you and the study team will know you are receiving buntanetap. It plans to enroll 500 participants.
- What's involved
- You would take buntanetap capsules 30 mg by mouth daily after a screening period of up to 42 days. The study will last for 36 months, with regular assessments.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary safety outcomes are measured at 36 months of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Buntanetap in Participants With PD
At a glance
Conditions
NCT07284784
Where you'd take part
This study runs at 27 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Abington Neurology
Willow Grove, Pennsylvaniastudy coordinator listed
Recruiting
Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
DeLand, Floridastudy coordinator listed
Recruiting
Arrow Clinical Trials
Daytona Beach, Floridastudy coordinator listed
Recruiting
Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
Sun City, Arizonastudy coordinator listed
Recruiting
Cenexel Rocky Mountain Clinical Research
Englewood, Coloradostudy coordinator listed
Recruiting
Central Texas Neurology
Round Rock, Texasstudy coordinator listed
Recruiting
Conquest Research
Winter Park, Floridastudy coordinator listed
Recruiting
Duke Department of Neurosurgery
Durham, North Carolinastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Laurie Sanders, Ph.D. · PRINCIPAL_INVESTIGATOR · Duke Clinical Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Safety of buntanetap36-months of treatment
Safety assessments of participants with PD receiving treatment with buntanetap
- Adverse Events (AE)36-months of treatment
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention
- Treatment Emergent Adverse Events (TEAE)36-months of treatment
TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state
- Serious Adverse Events (SAE)36-months of treatment
SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly